17.01.2014 • NewsCarlylehepatitis CHIV

Carlyle Wins J&J Diagnostic Unit

As expected, U.S. private equity investor Carlyle has been given the nod to acquire the ortho clinical diagnostics unit of compatriot pharmaceutical producer Johnson & Johnson (J&J). The selling price of $4.15 billion was in line with analysts' estimates. Carlyle said it plans to close the deal by the middle of this year. The business, a small player in a market dominated by larger companies, manufactures blood-screening equipment and laboratory blood tests as well as tests capable of identifying blood types and screening for viruses such as HIV and hepatitis C. J&J announced at the beginning of 2013 that it was exploring strategic alternatives for the activities.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.